Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia

Ibrutinib in the Treatment of Refractory Chronic Lymphocytic Leukemia

Background & Aims. This paper presents the results of the observational study of ibrutinib in patients with chronic lymphocytic leukemia (CLL), conducted in SP Botkin Municipal Clinical Hospital. The main objective was the analysis of complications of ibrutinib and identification of factors, inf...

Full description

Saved in:
Bibliographic Details
Main Authors: EA Nikitin, EA Dmitrieva, MA Panteleev, EI Emelina, VL Ivanova, YuB Kochkareva, EG Arshanskaya, IE Lazarev, EE Markova, LA Mukha, NG Novitskaya, MM Pankrashkina, VV Glazunova, AV Shubina, SA Chernysh, NK Khuazheva, EV Naumova, SA Lugovskaya, ME Pochtar’, TN Obukhova, OYu Vinogradova, GE Gendlin, VV Ptushkin
Format: Article
Language:Russian
Published: Practical Medicine Publishing House 2017-07-01
Series:Клиническая онкогематология
Subjects:
chronic lymphocytic leukemia
del 17p
TP53
refractory CLL
ibrutinib
bleeding
atrial fibrillation
Online Access:http://bloodjournal.ru/wp-content/uploads/2017/09/1.pdf
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items